UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~ August 116, 2025

ENTRADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	~~001-40969~~	~~81-3983399~~	001-40969	81-3983399
(State or other jurisdiction	(Commission	(I.R.S. Employer
(State or other jurisdictionof incorporation)			(CommissionFile Number)	(I.R.S. EmployerIdentification No.)
of incorporation)	File Number)	Identification No.)


One Design Center Place
Suite 17-500
Boston, MA						02210
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (857) 520-9158

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

~~Trading Symbol(s)~~

~~Name of each exchange on which registered~~

TradingSymbol(s)

Name of each exchangeon which registered

Common Stock, $0.0001 par value per share

~~TRDA~~

~~The Nasdaq Global Market~~

TRDA

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ o

Item 52.~~07.~~02 Results ~~Submission~~ of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

On ~~June~~August 116, 2025, Entrada Therapeutics, Inc. ~~(the “Company”)~~announced ~~held~~ its ~~2025~~financial ~~Annual~~results ~~Meeting~~for ~~of Stockholders (~~the ~~“Annual~~quarter ~~Meeting”)~~ended inJune ~~a virtual-only format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 25~~30, 2025 ~~with the Securities~~ and ~~Exchange~~other ~~Commission~~corporate ~~under Section 14(a) of the Securities Exchange Act of 1934, as amended~~updates. ~~As of~~A ~~the~~copy ~~close~~ of ~~business on April 14, 2025,~~ the ~~record~~press ~~date~~release ~~for~~in ~~the~~connection ~~Annual~~with ~~Meeting,~~ the ~~number~~announcement ofis ~~shares~~being offurnished ~~the~~as ~~Company’s~~Exhibit ~~common stock, $0~~99.~~0001~~1 ~~par value per share (“Common Stock”), outstanding and entitled~~ to ~~vote~~this atCurrent ~~the~~Report ~~Annual~~on ~~Meeting~~Form ~~was 37,953,417~~8-K. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 30,259,526, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Annual Meeting.

AtThe ~~the~~information ~~Annual~~in ~~Meeting,~~this ~~the~~Current ~~Company’s~~Report ~~stockholders were~~on ~~asked~~Form to8-K ~~vote~~(including onExhibit ~~the~~99.1 ~~following~~attached ~~matters,~~hereto) ~~which~~is ~~are~~intended ~~described~~to inbe ~~detail~~furnished inand ~~the~~shall ~~Proxy~~not ~~Statement:~~be ~~(i)~~deemed to“filed” ~~elect~~for ~~three~~purposes ~~Class~~of ISection ~~director nominees~~18 toof the ~~Company’s~~Securities ~~Board~~Exchange Act of ~~Directors~~1934, as amended (the “~~Board~~Exchange Act”), ~~each~~or tootherwise ~~serve~~subject ~~until~~to the ~~Company’s~~liabilities ~~2028 annual meeting~~ of ~~stockholders~~that ~~and~~section, ~~until~~nor ~~his~~shall orit ~~her~~be ~~respective~~deemed ~~successor~~incorporated ~~has~~by ~~been~~reference ~~duly~~in ~~elected~~any ~~and~~filing ~~qualified,~~under orthe ~~until~~Securities ~~his~~Act orof ~~her~~1933, ~~earlier~~as ~~death~~amended, ~~resignation~~ or ~~removal (“Proposal No. 1”) and (ii) to ratify~~ the ~~appointment~~Exchange ofAct, ~~Ernst~~except ~~& Young LLP~~ as ~~the~~expressly ~~Company’s~~set ~~independent registered~~forth ~~public~~by ~~accounting~~specific ~~firm~~reference ~~for~~in ~~the~~such ~~fiscal year ending December 31, 2025 (“Proposal No~~filing. ~~2”).~~

~~The~~Item ~~voting~~9.01 Financial ~~results~~Statements ~~reported~~and ~~below are final~~Exhibits.

~~Proposal No~~(d)Exhibits. 1

~~Dipal~~The ~~Doshi,~~following ~~Kush~~exhibit M.relating ~~Parmar, M.D., Ph.D. and Mary Thistle were duly elected~~ to ~~the~~Item ~~Board as Class I directors~~2.02 ~~The results~~ of ~~the~~this ~~stockholders’~~Form ~~vote~~8-K ~~with~~shall ~~respect~~be deemed to ~~the~~be ~~election were~~furnished asand ~~follows~~not filed:

CLASS I DIRECTOR NOMINEES	FOR		WITHHELD		BROKER NON-VOTES
99.1		Press Release issued by Entrada Therapeutics, Inc. on August 6, 2025
Dipal Doshi		27,809,399		429,248		2,020,879
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).
Kush M. Parmar, M.D., Ph.D.		24,883,797		3,354,850		2,020,879
Mary Thistle		27,768,093		470,554		2,020,879

~~Proposal No. 2~~SIGNATURE

~~The~~Pursuant ~~appointment~~to ofthe ~~Ernst~~requirements &of ~~Young LLP as~~ the ~~Company’s~~ ~~independent~~Securities ~~registered~~Exchange ~~public~~Act ~~accounting~~of ~~firm~~1934, ~~for~~ the ~~fiscal~~registrant ~~year~~has ~~ending~~duly ~~December~~caused ~~31,~~this ~~2025~~report ~~was~~to ~~ratified.~~be ~~The~~signed ~~results~~on ~~of the~~its ~~stockholders’~~behalf ~~vote~~by ~~with~~the ~~respect~~undersigned tohereunto ~~such~~duly ~~ratification~~authorized. ~~were as follows:~~

FOR	AGAINST		ABSTAIN
		Entrada Therapeutics, Inc.
30,176,125		74,925		8,476
Date: August 6, 2025				/s/ Dipal Doshi
				Dipal Doshi
				Chief Executive Officer

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Entrada Therapeutics, Inc.
Date: June 11, 2025		/s/ Dipal Doshi
		Dipal Doshi
		Chief Executive Officer

Filing Compare · Entrada Therapeutics, Inc.